Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).
about
Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease.Small-molecule anti-inflammatory drug compositions for the treatment of asthma: a patent review (2013 - 2014).Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological TreatmentDiscovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists.Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis.
P2860
Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhaled muscarinic antagonists ...... nt developments (2006 - 2010).
@en
Inhaled muscarinic antagonists ...... tents and current developments
@nl
type
label
Inhaled muscarinic antagonists ...... nt developments (2006 - 2010).
@en
Inhaled muscarinic antagonists ...... tents and current developments
@nl
prefLabel
Inhaled muscarinic antagonists ...... nt developments (2006 - 2010).
@en
Inhaled muscarinic antagonists ...... tents and current developments
@nl
P2093
P2860
P1476
Inhaled muscarinic antagonists ...... nt developments (2006 - 2010).
@en
P2093
Maria Prat
Montserrat Miralpeix
Silvia Fonquerna
P2860
P304
P356
10.1517/13543776.2011.596528
P407
P577
2011-06-25T00:00:00Z